PeerBridge Health, Inc.

Wireless connectivity enablement with AT&T helps Peerbridge expand access to AI-driven cardiac care LAS VEGAS, March 3, 2025 /PRNewswire/ -- Peerbridge Health is ushering in the next generation of remote cardiac monitoring at the HIMSS Global Health Conference with the introduction of Cor MDx, the world's most powerful cardiac IoT wearable. COR MDx will be showcased at AT&T Booth#1732, underscoring its role in transforming cardiac care through cutting-edge technology. Cor MDx represents a complete reimagining of traditional ECG wearable patches. The device combines best-in-class signal fidelity and real-time multi-lead streaming and connectivity over BLE and LTE to offer a seamless, cost-effective solution for cardiac care. This step forward in technology delivers non-invasive cardiovascular and cardiopulmonary measurements to enable the 30+ indications previously announced in Peerbridge's COR-INSIGHT trial. Bridging Gaps in Cardiac Care with Advanced AI With an estimated 40 million Americans suffering from undiagnosed heart failure and 85% of rural counties lacking a cardiologist, Cor MDx is designed to expand access to early detection and intervention for those in need but being missed today. The wearable will support full-spectrum monitoring, from 14-day Holter monitoring and mobile cardiac telemetry (MCT) to advanced hemodynamic assessments and acute care telemetry. "Cor MDx sets a new benchmark in remote cardiac diagnostics and monitoring," said Chris Darland, CEO of Peerbridge Health. "This device not only enhances diagnostic yield but also dramatically reduces costs, enabling hospitals, physicians, and patients to access critical cardiac insights like never before. Our ongoing collaboration with AT&T further strengthens our ability to deliver seamless real-time connectivity, ensuring continuous cardiac monitoring for patients everywhere and the providers caring for them." Enabling Real-Time, AI-Driven Cardiac Monitoring AT&T provides the IoT backbone for Cor MDx, enabling real-time data transmission, remote study reconfiguration, and seamless management over LTE, for optimal patient monitoring. "AT&T is helping Peerbridge through secure, intelligent connectivity," said David Garver, area vice president, AT&T Connected Solutions. "We support Peerbridge Health's Cor MDx wearable with wireless connectivity so they can deliver AI-powered, hospital-grade cardiac diagnostics and monitoring. Peerbridge's technology enables predictive, personalized care to help enhance the quality of care for patients." Expanding Access at Ultra-low Cost "In our view, reaching underserved communities means bringing hospital-grade tools directly to their doorsteps in the most inexpensive way imaginable. Achieving this goal required a complete re-tooling of the hardware, software and cost structure for Peerbridge Health," added Darland. "We're fortunate to have AT&T supporting our mission of delivering ultra low-cost cardiac diagnostics and monitoring to millions of patients falling between the cracks today." Regulatory & Market Outlook Cor MDx is expected to launch commercially in the second half of 2025, pending regulatory approvals. The device will initially be deployed in the COR-INSIGHT clinical trials involving up to 15,000 participants at leading hospitals, outpatient clinics, and medical research centers. Hospital systems participating in the HeartX program, led by HealthTech Arkansas and MedAxiom, will have first access to the Cor MDx device as the teams work together to deliver improved outcomes to rural patients across the U.S. About Peerbridge Health Peerbridge Health is revolutionizing cardiac care as the first company to bring the quality and accuracy of hospital-grade cardiac diagnostics and monitoring to the home. The company's AI-enabled device, Peerbridge Cor®, includes a three-lead, patented AECG wearable device that features a design based on the Einthoven Triangle. The Peerbridge platform leverages ECG to diagnose and monitor the most important elements of cardiac care at a lower cost than ever before. Data captured provides actionable insights that promote early invention, reduce hospital visits and saves lives. For more, go to peerbridgehealth.com or visit our LinkedIn page. Media Contact: Kim Mohr Amendola Communications for Peerbridge Health 949-322-3733; [email protected] SOURCE Peerbridge Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Trial is first of its kind to measure EF severity direct-from-ECG NEW YORK, July 24, 2024 /PRNewswire/ -- Peerbridge Health today announced the beginning of enrollment for its Ejection Fraction AI-enabled Clinical Trial (EF-ACT) pivotal trial to determine Left Ventricular Ejection Fraction (LVEF) severity directly from its AI-enabled Peerbridge Cor™ remote wearable electrocardiogram (ECG) device. This will enable on-demand assessments of EF Severity on the American Society of Echocardiography scale and will be available anytime in all settings – in clinic and at home. Ejection Fraction Severity categories help clinicians assess the severity of heart dysfunction, guiding treatment decisions and prognostic evaluations. The Ejection Fraction (EF) severity categories on the American Society of Echocardiography (ASE) scale are defined based on the percentage of blood that the left ventricle pumps out with each contraction. The trial, whose announcement comes following in-depth discussions with leading cardiology experts and the Food and Drug Administration, will involve approximately 1,000 patients across multiple trial centers, including Northwell Health, Hackensack Meridian Health, Mount Sinai Health System, LeBauer-Brodie Center for Cardiovascular Research at Cone Health and Orange County Heart Institute in California. This pivotal trial comes on the heels of a successful feasibility trial in 2023. "This is the first pivotal trial to study direct-from-ECG ejection fraction (EF) severity at this level of fidelity," said Peerbridge Health CEO and President Chris Darland. "The findings of this trial could have a profound effect on access and affordability of cardiac care." Echocardiograms are the most common measurement tool for ejection fraction, but they must be performed in a clinic or hospital setting. This can pose challenges due to delays in scheduling, limited staffing resources, lack of access, and higher costs. The Peerbridge Health platform offers a seamless remote monitoring option that is less expensive, reducing patient burden and enabling more frequent assessments. Coupled with rhythm changes, direct-from-COR EF Severity would add valuable context for clinical decision-making, enhancing intervention adjustments. "Peerbridge's EF technology addresses a critical gap in remote healthcare by providing a rapid, convenient, noninvasive, and cost-effective method to better understand a patient's cardiac status," said Nicolas Skipitaris, MD, Chairman of Cardiovascular Medicine at Northwell Health's Westchester Hospitals. "Early and accurate remote detection of potential cardiac dysfunction allows us to intervene more quickly and more effectively, improving patient outcomes at a fraction of the cost." Development of the Peerbridge Health Advanced Diagnostics platform began in Spring 2023 and Ejection Fraction Severity is the first of three AI-enabled pivotal trials for Software-as-a-Medical Device (SaMD), with Heart Failure Detection and Sleep Apnea Diagnosis to follow. "We're very grateful to our clinical partners and are focused on continuing to deliver innovation to care providers across the country," Darland added. "Our goal remains to reach the millions of aging patients who don't have the luxury of time or money to proactively see a cardiologist to avoid a losing battle with heart disease. The team at Peerbridge takes this responsibility seriously. I am confident that our technology will provide meaningful impact in the near- and long-term." About Peerbridge Health Peerbridge Health is revolutionizing cardiac care as the first company to bring the quality and accuracy of hospital-grade cardiac diagnostics and monitoring to the home. The company's AI-enabled device, Peerbridge Cor™, includes a three-lead, patented AECG wearable device that features a design based on the Einthoven Triangle. The Peerbridge platform leverages ECG to diagnose and monitor the most important elements of cardiac care at a lower cost than ever before. Data captured provides actionable insights that promote early invention, reduce hospital visits and saves lives. For more, go to peerbridgehealth.com or visit our LinkedIn page. Media Contact: Kim Mohr Amendola Communications for Peerbridge Health 949-322-3733; [email protected] SOURCE Peerbridge Health

SCOTTSDALE, Ariz., April 23, 2024 /PRNewswire/ -- Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, today announced that it has been selected to implement a national PR program by Peerbridge Health, developer of a hospital-grade, remote diagnostic and monitoring platform that harnesses artificial intelligence (AI) for early detection of heart failure and other conditions. "Amendola comes highly recommended by healthcare technology peers, giving us confidence that its industry-specific expertise and successful track record will produce valuable results," said Chris Darland, CEO of Peerbridge Health. "We look forward to working with Amendola to educate the industry on the life-saving potential of early detection of heart failure through AI-enabled remote monitoring technology, which we are able to offer at a significantly lower cost compared to traditional methods." More than 6 million Americans live with heart failure, and each year around 1 million new cases are diagnosed in adults 55 years of age and over. Heart failure is the second-leading cause of hospitalization in the U.S. and the leading cause of hospitalization among adults 65 and older. To reduce the impact of heart failure, Peerbridge Health has developed the Peerbridge Cor™, an AI-enabled, 3-lead, 2-channel wireless ambulatory ECG device. A recent feasibility trial showed the device had a nearly 96% accuracy rate in identifying heart failure in patients utilizing ECG as the only input. "Heart failure is a serious condition that is often only diagnosed after a visit to the emergency room," said agency CEO Jodi Amendola. "We are pleased to partner with Peerbridge Health in its efforts to extend access to care, improve outcomes for cardiac patients, and reduce the financial burden of this disease." About Amendola Amendola is an award-winning, insights-driven public relations and marketing firm that integrates media relations, social media, content and lead gen programs to move healthcare, life sciences/pharma and healthcare IT decision-makers to action. The agency represents some of the industry's best-known brands as well as groundbreaking startups that are disrupting the status quo. Nearly 90% of its client base represents multi-year clients and/or repeat client executives. Amendola's seasoned team of PR and marketing pros understand the ongoing complexities of the healthcare ecosystem and provide strategic guidance and creative direction to drive positive ROI, boost reputation and increase market share. Making an impact since 2003, Amendola combines traditional and digital media to fuel meaningful and measurable growth. For more information about the industry's "A-Team," visit , and follow us on Twitter and LinkedIn. About Peerbridge Health Peerbridge Health is revolutionizing cardiac care as the first company to bring the quality and accuracy of hospital-grade cardiac diagnostics to the home. The company's AI-enabled device, Peerbridge Cor™, includes a three-lead, patented AECG wearable device that features a design based on the Einthoven Triangle. The Peerbridge platform leverages ECG to diagnose and monitor the most important elements of cardiac care at a lower cost than ever before. Data captured provides actionable insights that promote early invention, reduce hospital visits and saves lives. For more, go to peerbridgehealth.com or visit our LinkedIn page. Media Contact: Marcia G. Rhodes, [email protected], Amendola Communications SOURCE Amendola Communications